Tirzepatide

Overview

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. It is engineered largely from the sequence of naturally occurring gastric inhibitory polypeptide (GIP), with a C20 fatty diacid moiety attached to the peptide backbone to drastically extend plasma half-life and enable once-weekly dosing [1]. As a first-in-class “twincretin,” tirzepatide simultaneously activates both the GIP and GLP-1 receptors — a mechanistic step beyond GLP-1-only agonists such as semaglutide.

Tirzepatide achieved its first FDA approval in May 2022 under the brand name Mounjaro for the treatment of Type 2 Diabetes [2]. Following the unprecedented weight-loss results of the SURMOUNT clinical trials, the same peptide was approved in November 2023 under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight [3]. Most recently, Zepbound’s FDA approval was expanded in 2024 to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity [5].

Commercial access has expanded significantly. In addition to traditional specialty pharmacies, Eli Lilly now sells tirzepatide direct-to-consumer via LillyDirect, and major telehealth providers such as Ro and Hims & Hers offer prescribed access to compounded or brand-name versions. A separate research-chemical market also sells lyophilized tirzepatide to non-prescription customers.

Research Areas and Claims

Widely referred to in wellness marketing as the “King of Weight Loss Peptides,” tirzepatide is positioned as a superior successor to semaglutide (Ozempic/Wegovy). Peer-reviewed Phase 3 evidence supports several of these claims directly:

• Obesity & Weight Loss (FDA-approved): At 72 weeks in SURMOUNT-1, the 15 mg dose produced an average weight loss of 20.9% versus 3.1% for placebo. More than half of participants on the highest dose lost ≥20% of body weight — a threshold previously only consistently achieved by bariatric surgery [3].

• Type 2 Diabetes (FDA-approved): In SURPASS-2, a landmark head-to-head trial against semaglutide 1 mg, tirzepatide at all tested doses (5, 10, 15 mg) was statistically superior for both HbA1c reduction and total body weight loss [2].

• Obstructive Sleep Apnea (FDA-approved): In SURMOUNT-OSA, tirzepatide significantly reduced the apnea-hypopnea index (AHI) by up to 62.8%, effectively resolving sleep apnea in a large proportion of patients and leading directly to an FDA approval for this new indication [5].

• Combined Obesity + T2D: SURMOUNT-2 evaluated tirzepatide in patients with both obesity and Type 2 Diabetes — typically harder to achieve weight loss. The 15 mg dose produced a 14.7% average body weight reduction with profound cardiometabolic improvements [4].

• Cardiometabolic Markers: Across SURPASS and SURMOUNT trials, tirzepatide substantially improved lipid profiles, blood pressure, and inflammatory markers in addition to glycemic control [2][4].

Mechanism of Action

1. GLP-1 Receptor Agonism: Slows gastric emptying, increases glucose-dependent insulin secretion, and signals the brain to reduce appetite and increase satiety [1].
2. GIP Receptor Agonism: Synergistically enhances glucose-dependent insulin secretion, suppresses glucagon, and uniquely improves lipid metabolism and fat utilization in white adipose tissue. This is the component missing from semaglutide’s mechanism [1].
3. Dual-Action Synergy: The combination amplifies appetite suppression in the brain while accelerating systemic metabolic efficiency, driving the profound weight loss seen in the SURMOUNT trials [4].
4. Extended Half-Life: The C20 fatty diacid moiety binds serum albumin, producing a ~5-day plasma half-life that enables a once-weekly subcutaneous dosing schedule.

Dosing Schedule

• Route: Subcutaneous (SC) injection — abdomen, thigh, or upper arm. Commercial product supplied in single-dose auto-injector pens.

• Frequency: Once weekly.

• Initiation Dose: 2.5 mg weekly for 4 weeks. (Intended for titration only — not considered a therapeutic maintenance dose.)

• Escalation: Increase in 2.5 mg increments every 4 weeks based on tolerance.

• Maintenance Doses: 5 mg, 10 mg, or 15 mg once weekly, depending on tolerance and required efficacy. 15 mg is the maximum approved weekly dose.

• Oral Route: Not viable. Tirzepatide is rapidly degraded in the GI tract; no approved or clinically viable oral formulation exists.

Clinical Trials

Tirzepatide has an exceptionally robust Phase 3 evidence base built on Eli Lilly’s two pivotal registrational programs: SURPASS (Type 2 Diabetes) and SURMOUNT (Obesity, including the sleep apnea extension). The trials below are the four most commonly cited.

Safety & Regulatory Notes

Research-Chemical Vendor Directory

Pricing collected April 2026. Standard presentation: 10 mg lyophilized powder, reconstituted for SC injection. Sorted by $/mg ascending.

Simple mean across 5 vendor listings: ~$11.30/mg. Research-chemical grade — not for human consumption per vendor disclaimers.

References

1. [1]

   Min T, Bain SC. “The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.” Diabetes Ther. 2021. pubmed.ncbi.nlm.nih.gov/33428135

2. [2]

   Frias JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/34170647

3. [3]

   Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024

4. [4]

   Garvey WT, et al. “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” Lancet. 2023. pubmed.ncbi.nlm.nih.gov/37385275

5. [5]

   Malhotra A, et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA).” N Engl J Med. 2024. pubmed.ncbi.nlm.nih.gov/38912643

6. [6]

   Limitless Life Nootropics webpage. “Tirzepatide.” limitlesslifenootropics.com/product/tirzepatide (accessed Apr 21, 2026)

7. [7]

   Core Peptides webpage. “Tirzepatide 10mg.” corepeptides.com/peptides/tirzepatide-10mg (accessed Apr 21, 2026)

8. [8]

   Skye Peptides webpage. “Tirzepatide 10mg.” skyepeptides.com/product/tirzepatide (accessed Apr 21, 2026)

9. [9]

   Aminos Research webpage. “Tirzepatide 10mg.” aminos-research.com/product/tirzepatide-10mg (accessed Apr 21, 2026)

10. [10]

    Arctic Peptides webpage. “Tirzepatide 10mg.” arcticpeptides.com/product/tirzepatide-10mg (accessed Apr 21, 2026)